Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 323.00
Bid: 321.50
Ask: 323.50
Change: 2.50 (0.78%)
Spread: 2.00 (0.622%)
Open: 316.50
High: 323.00
Low: 315.00
Prev. Close: 320.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: Record down as managed assets decline

Fri, 20th Oct 2023 10:02

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

----------

SMALL-CAP - WINNERS

----------

Regional REIT Ltd, up 4.4% at 27.52 pence, 12-month range 25.57p-69.60p. This is after the London-based real estate investment trust's share price falls 2.0% in the last five days and 49% in the last six months. Last month, it reported a first half pretax loss of GBP12.1 million from a profit of GBP28.3 million a year earlier.

----------

Oxford BioMedica PLC, up 3.7% at 260.26p, 12-month range 236.50p-575.00p. This is after the Oxfordshire, England-based gene and cell therapy group's share price falls 7.8% in the last five days and 39% in the last six months. Last month, it reported that its first half pretax loss widened to GBP52.3 million from GBP27.4 million, although shares rose on noting it was in exclusive talks to buy ABL Europe from Institut Merieux SA for EUR15 million.

----------

SMALL-CAP - LOSERS

----------

Record PLC, down 4.9% at 69.4p, 12-month range 68.12p-102.00p. The currency and derivatives manager said that plans for diversification are progressing well, despite seeing assets under management decline in the second quarter. For the three months ended September 30, it says assets under management equivalents fell to USD84.5 million, from USD86.4 million at the end of June. Dynamic hedging assets under management fall 5.2% to USD14.5 billion from USD15.3 billion in the first quarter, while passive hedging assets fall 1.8% to USD60.5 billion from USD61.6 billion. "Our plans for diversification through our asset management and digital asset businesses continue to progress well, albeit in places more gradually than initially envisaged, and I look forward to giving more detail on our strategic progress at our forthcoming half-year results in November," says Chief Executive Leslie Hill.

----------

Sabre Insurance Group PLC, down 4.3% at 145.5p, 12-month range 81.90p-168.00p. Barclays raises its price target for the Dorking, England-based motor insurance underwriter to 171p from 157p, rating the stock at 'overweight'. Sabre Insurance shares were up 3.3% at 155.00p in London on Thursday around noon, after celebrating a sharp increase in gross written premiums in the last nine months, despite Motorcycle premiums plummeting. It also raised its full-year guidance. Gross written premiums increased 20% in the nine months ended September 30, to GBP162.2 million from GBP135.7 million. In 2022, they totalled GBP171.3 million.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
6 May 2020 12:52

Oxford Biomedica swings to loss as licensing revenue falls

(Sharecast News) - Gene and cell therapy company Oxford Biomedica reported an improvement in bioprocessing and commercial development revenues to ?47.3m in its preliminary results on Wednesday, from ?40.5m.

Read more
29 Apr 2020 16:13

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
28 Apr 2020 11:13

Liberum hikes target price on Oxford Biomedica

(Sharecast News) - Analysts at Liberum hiked their target price on gene and cell therapy company Oxford BioMedica from £8.60 per share to £10.90 on Tuesday, citing demand at its new OxBox manufacturing facility.

Read more
8 Apr 2020 16:13

Oxford Biomedica joins Covid-19 vaccine consortium

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has joined a consortium led by the Jenner Institute at Oxford University, it announced on Wednesday, to rapidly develop, scale-up and manufacture a potential vaccine candidate for Covid-19, called 'ChAdOx1 nCov-19'.

Read more
8 Apr 2020 14:46

UK TRADING UPDATE SUMMARY: Novacyt Gets WHO Covid-19 Test Kit Okay

UK TRADING UPDATE SUMMARY: Novacyt Gets WHO Covid-19 Test Kit Okay

Read more
20 Mar 2020 15:57

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

Read more
19 Mar 2020 10:59

Oxford Biomedica Expects 2019 Loss As Chair Steps Down, Signs New Deal

Oxford Biomedica Expects 2019 Loss As Chair Steps Down, Signs New Deal

Read more
4 Feb 2020 12:10

Oxford Biomedica Sells USD8.4 Million In Orchard Therapeutics Shares

Oxford Biomedica Sells USD8.4 Million In Orchard Therapeutics Shares

Read more
19 Dec 2019 16:27

Oxford Biomedica Extends Agreement With Novartis By Five Years

Oxford Biomedica Extends Agreement With Novartis By Five Years

Read more
30 Sep 2019 09:55

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

Read more
28 May 2019 13:18

Novo Holdings pours ?53.5m into Oxford Biomedica

(Sharecast News) - Gene and cell therapy company Oxford Biomedica announced on Tuesday that Novo Holdings has agreed to invest up to £53.5m in the group, in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase.

Read more
15 Mar 2019 12:46

Friday broker round-up

(Sharecast News) - Bakkavor Group: Berenberg downgrades to sell with a target price of 105p.

Read more
14 Mar 2019 14:16

Oxford Biomedica swings to positive earnings in 2018

(Sharecast News) - Gene and cell therapy group Oxford Biomedica reported a 72% increase in gross income in its preliminary results for the year ended 31 December on Thursday, to £67.9m.

Read more
12 Mar 2019 10:10

Oxford Biomedica enters research collaboration with Microsoft

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has entered into a research and development collaboration with Microsoft Research, it announced on Tuesday, to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning.

Read more
23 Nov 2018 10:59

Oxford BioMedica forms new digital framework initiative

(Sharecast News) - Gene and cell therapy group Oxford BioMedica announced the formation of a new digital framework initiative on Friday, which it said would streamline the production of next-generation medicines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.